Cell Respiration
Respiration
Oxygen Consumption
Cheyne-Stokes Respiration
Mitochondria
Oxidative Phosphorylation
Electron Transport
Oxygen
Mitochondria, Liver
Anaerobiosis
Antimycin A
Carbon Dioxide
Uncoupling Agents
Cyanides
Electron Transport Complex IV
Energy Metabolism
Oligomycins
Oxidation-Reduction
Succinates
Mitochondria, Muscle
Mitochondrial Proteins
Adenosine Triphosphate
Nitrates
Succinic Acid
Carbon
Potassium Cyanide
Respiratory Rate
Cytochromes
Oxidoreductases
Polarography
Shewanella
Glycolysis
Photosynthesis
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone
Adenosine Diphosphate
Electron Transport Chain Complex Proteins
Electron Transport Complex I
NAD
Soil
Biomass
Atractyloside
Carbon Cycle
Respiratory Mechanics
2,4-Dinitrophenol
Tissues
Succinate Dehydrogenase
Glucose
Respiratory Physiological Phenomena
Respiratory Physiological Processes
Reactive Oxygen Species
Nitrate Reductase
Membrane Potential, Mitochondrial
Ubiquinone
Carbonyl Cyanide m-Chlorophenyl Hydrazone
Mitochondrial Swelling
Temperature
Pyruvic Acid
Tetramethylphenylenediamine
Citrate (si)-Synthase
Plant Leaves
Amobarbital
Citric Acid Cycle
NADH Dehydrogenase
Electron Transport Complex II
Nitrogen
Trees
Models, Biological
Wolinella
Protons
Hydrogen-Ion Concentration
Cytochrome c Group
DNA, Mitochondrial
Metabolism
Membrane Potentials
Mitochondrial ADP, ATP Translocases
Nitrite Reductases
Sodium Cyanide
Ketoglutaric Acids
Carbohydrate Metabolism
Mutation
Nitrites
Hydrogen Peroxide
Oxidative Stress
Ecosystem
Chemoreceptor Cells
Intracellular Membranes
Fermentation
Electron Transport Complex III
Nitric Oxide
Respiratory Center
Arrhythmia, Sinus
Saccharomyces cerevisiae
Mitochondrial Membranes
Respiration, Artificial
Gene Expression Regulation, Bacterial
Culture Media
Mitochondrial Diseases
Tidal Volume
Body Temperature Regulation
Muscle, Skeletal
Cytochromes c
Escherichia coli
Rats, Wistar
Plant Roots
NADH, NADPH Oxidoreductases
Molecular Sequence Data
Denitrification
Sodium Azide
Respiratory-Gated Imaging Techniques
Calcium
Carbon Isotopes
Antimetabolites
Hydrogen
Bacteria
Voltage-Dependent Anion Channels
Plant Stems
Ascaridia
Submitochondrial Particles
Meclizine
Pulmonary Ventilation
Ion Channels
Adaptation, Physiological
Valinomycin
Heterotrophic Processes
Lactic Acid
Acetobacterium
Creatine
Acetates
Spectrophotometry
Soil Microbiology
Environment, Controlled
Amaranthus
Pinus sylvestris
Rats, Sprague-Dawley
Adipose Tissue, Brown
Rats, Inbred Strains
Deglutition
Nitrogen Fixation
Electrodes
Phosphocreatine
Biological Transport
Proton Pumps
Proton-Motive Force
Heme
Potassium
Shewanella putrefaciens
Brain Stem
Pinus
Iron-Sulfur Proteins
Glutamates
Sleep Apnea, Central
Partial Pressure
Biological Transport, Active
Glycerol
Rosales
NADP
Phenformin
Geobacter
Fatty Acids
Mitochondrial Membrane Transport Proteins
Creatine Kinase
Plant Proteins
Medulla Oblongata
Carotid Body
Positive-Pressure Respiration
Xanthium
Carcinoma, Ehrlich Tumor
Plants
Twelfth rib resection as an approach for portal vein cannulation in sheep. (1/3997)
A surgical technique involving resection of the twelfth rib was used to insert silastic cannulas into the portal veins of three sheep to study amino acid metabolism. Good exposure to the vein was achieved by this method although it required positive ventilation due to the penetration of the thoracic cavity. All cannulas were buried subcutaneously and exteriorized near the dorsal midline. This facilitated continuous infusion into the portal cannula without disturbing cannula placement. (+info)The impact of a multidisciplinary approach on caring for ventilator-dependent patients. (2/3997)
OBJECTIVE: To determine the clinical and financial outcomes of a highly structured multidisciplinary care model for patients in an intensive care unit (ICU) who require prolonged mechanical ventilation. The structured model outcomes (protocol group) are compared with the preprotocol outcomes. DESIGN: Descriptive study with financial analysis. SETTING: A twelve-bed medical-surgical ICU in a non-teaching tertiary referral center in Ogden, Utah. STUDY PARTICIPANTS: During a 54 month period, 469 consecutive intensive care patients requiring mechanical ventilation for longer than 72 hours who did not meet exclusion criteria were studied. INTERVENTIONS: A multidisciplinary team was formed to coordinate the care of ventilator-dependent patients. Care was integrated by daily collaborative bedside rounds, monthly meetings, and implementation of numerous guidelines and protocols. Patients were followed from the time of ICU admission until the day of hospital discharge. MAIN OUTCOME MEASURES: Patients were assigned APACHE II scores on admission to the ICU, and were divided into eight diagnostic categories. ICU length of stay, hospital length of stay, costs, charges, reimbursement, and in-hospital mortality were measured. RESULTS: Mortality in the preprotocol and protocol group, after adjustment for APACHE II scores, remained statistically unchanged (21-23%). After we implemented the new care model, we demonstrated significant decreases in the mean survivor's ICU length of stay (19.8 days to 14.7 days, P= 0.001), hospital length of stay (34.6 days to 25.9 days, P=0.001), charges (US$102500 to US$78500, P=0.001), and costs (US$71900 to US$58000, P=0.001). CONCLUSIONS: Implementation of a structured multidisciplinary care model to care for a heterogeneous population of ventilator-dependent ICU patients was associated with significant reductions in ICU and hospital lengths of stay, charges, and costs. Mortality rates were unaffected. (+info)Trigeminal and carotid body inputs controlling vascular resistance in muscle during post-contraction hyperaemia in cats. (3/3997)
1. In anaesthetized cats, the effects of stimulation of the receptors in the nasal mucosa and carotid body chemoreceptors on vascular resistance in hindlimb skeletal muscle were studied to see whether the responses were the same in active as in resting muscle. The measurements of vascular resistance were taken, first, in resting muscle, and second, in the immediate post-contraction hyperaemic phase that followed a 30 s period of isometric contractions. 2. Stimulation of the receptors in the nasal mucosa caused reflex apnoea and vasoconstriction in muscle. The latter response was attenuated when the test was repeated during post-contraction hyperaemia. 3. Stimulations of the carotid bodies were made during a period of apnoea evoked reflexly by electrical stimulation of both superior laryngeal nerves. This apnoea prevented any effects of changes in respiration on the carotid body reflex vascular responses. Stimulation of the carotid bodies evoked hindlimb muscle vasoconstriction. In the post-contraction hyperaemic period, the response was reduced or abolished. A similar attenuation of the reflex vasoconstrictor responses occurred in decentralized muscles stimulated through their motor roots in the cauda equina. 4. Evidence is presented that the attenuation of the vasoconstrictor responses evoked by the two reflexes is a phenomenon localized to the contracting muscles themselves resulting from an interaction between sympathetic neuronal activity and the local production of metabolites. 5. The results are discussed in relation to the metabolic needs of tissues in relation to asphyxial defence mechanisms such as occur in the diving response. (+info)Renal and hemodynamic effects of losartan in conscious dogs during controlled mechanical ventilation. (4/3997)
In 12 conscious dogs, we investigated whether the angiotensin II-receptor antagonist losartan increases renal sodium excretion and urine volume during controlled mechanical ventilation (CMV) with positive end-expiratory pressure. In four experimental protocols, the dogs were extracellular volume (ECV) expanded (electrolyte solution, 0.5 ml. kg-1. min-1 iv) or not and received losartan (100 micrograms. kg-1. min-1 iv) or not. They breathed spontaneously during the 1st and 4th hour and received CMV with positive end-expiratory pressure (mean airway pressure 20 cmH2O) during the 2nd and 3rd hours. In the expansion group, dogs with losartan excreted approximately 18% more sodium (69 +/- 7 vs. 38 +/- 5 micromol. min-1. kg-1) and 15% more urine during the 2 h of CMV because of a higher glomerular filtration rate (5.3 +/- 0.3 vs. 4.5 +/- 0.2 ml. min-1. kg-1) and the tubular effects of losartan. In the group without expansion, sodium excretion (2.0 +/- 0.6 vs. 2.6 +/- 1.0 micromol. min-1. kg-1) and glomerular filtration rate (3.8 +/- 0.3 vs. 3.8 +/- 0.4 ml. min-1. kg-1) did not change, and urine volume decreased similarly in both groups during CMV. Plasma vasopressin and aldosterone increased in both groups, and plasma renin activity increased from 4.9 +/- 0.7 to 7.8 +/- 1.3 ng ANG I. ml-1. h-1 during CMV in nonexpanded dogs without losartan. Mean arterial pressure decreased by 10 mmHg in nonexpanded dogs with losartan. In conclusion, losartan increases sodium excretion and urine volume during CMV if the ECV is expanded. If the ECV is not expanded, a decrease in mean arterial blood pressure and/or an increase in aldosterone and vasopressin during CMV attenuates the renal effects of losartan. (+info)Outcome for cancer patients requiring mechanical ventilation. (5/3997)
PURPOSE: To describe hospital survival for cancer patients who require mechanical ventilation. MATERIALS AND METHODS: A prospective, multicenter observational study was performed at five academic tertiary care hospitals. Demographic and clinical variables were obtained on consecutive cancer patients at initiation of mechanical ventilation, and information on vital status at hospital discharge was acquired. RESULTS: Our analysis was based on 782 adult cancer patients who met predetermined inclusion criteria. The overall observed hospital mortality was 76%, with no statistically significant differences among the five study centers. Seven variables (intubation after 24 hours, leukemia, progression or recurrence of cancer, allogeneic bone marrow transplantation, cardiac arrhythmias, presence of disseminated intravascular coagulation, and need for vasopressor therapy) were associated with an increased risk of death, whereas prior surgery with curative intent was protective. The predictive model based on these variables had an area under the receiver operating characteristic curve of 0.736, with Hosmer-Lemeshow goodness-of-fit statistics of 7.19; P = .52. CONCLUSION: This model can be used to estimate the probability of hospital survival for classes of adult cancer patients who require mechanical ventilation and can help to guide physicians, patients, and families in deciding goals and direction of treatment. Prospective independent validation in different medical settings is warranted. (+info)Continuous arterial P(O2) and P(CO2) measurements in swine during nitrous oxide and xenon elimination: prevention of diffusion hypoxia. (6/3997)
BACKGROUND: During nitrous oxide (N2O) elimination, arterial oxygen tension (PaO2) decreases because of the phenomenon commonly called diffusive hypoxia. The authors questioned whether similar effects occur during xenon elimination. METHODS: Nineteen anesthetized and paralyzed pigs were mechanically ventilated randomly for 30 min using inspiratory gas mixtures of 30% oxygen and either 70% N2O or xenon. The inspiratory gas was replaced by a mixture of 70% nitrogen and 30% oxygen. PaO2 and carbon dioxide tensions were recorded continuously using an indwelling arterial sensor. RESULTS: The PaO2 decreased from 119+/-10 mm Hg to 102+/-12 mm Hg (mean+/-SD) during N2O washout (P<0.01) and from 116+/-9 mm Hg to 110+/-8 mm Hg during xenon elimination (P<0.01), with a significant difference (P<0.01) between baseline and minimum PaO2 values (deltaPaO2, 17+/-6 mm Hg during N2O washout and 6+/-3 mm Hg during xenon washout). The PaCO2 value also decreased (from 39.3+/-6.3 mm Hg to 37.6+/-5.8 mm Hg) during N2O washout (P<0.01) and during xenon elimination (from 35.4+/-1.6 mm Hg to 34.9+/-1.6 mm Hg; P< 0.01). The deltaPaCO2 was 1.7+/-0.9 mm Hg in the N2O group and 0.5+/-0.3 mm Hg in the xenon group (P<0.01). CONCLUSION: Diffusive hypoxia is unlikely to occur during recovery from xenon anesthesia, probably because of the low blood solubility of this gas. (+info)Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. (7/3997)
BACKGROUND: The safety and efficacy of inhaled glucocorticoid therapy for asthma stimulated its use in infants to prevent bronchopulmonary dysplasia. We tested the hypothesis that early therapy with inhaled glucocorticoids would decrease the frequency of bronchopulmonary dysplasia in premature infants. METHODS: We conducted a randomized, multicenter trial of inhaled beclomethasone or placebo in 253 infants, 3 to 14 days old, born before 33 weeks of gestation and weighing 1250 g or less at birth, who required ventilation therapy. Beclomethasone was delivered in a decreasing dosage, from 40 to 5 microg per kilogram of body weight per day, for four weeks. The primary outcome measure was bronchopulmonary dysplasia at 28 days of age. Secondary outcomes included bronchopulmonary dysplasia at 36 weeks of postmenstrual age, the need for systemic glucocorticoid therapy, the need for bronchodilator therapy, the duration of respiratory support, and death. RESULTS: One hundred twenty-three infants received beclomethasone, and 130 received placebo. The frequency of bronchopulmonary dysplasia was similar in the two groups: 43 percent in the beclomethasone group and 45 percent in the placebo group at 28 days of age, and 18 percent in the beclomethasone group and 20 percent in the placebo group at 36 weeks of postmenstrual age. At 28 days of age, fewer infants in the beclomethasone group than in the placebo group were receiving systemic glucocorticoid therapy (relative risk, 0.6; 95 percent confidence interval, 0.4 to 1.0) and mechanical ventilation (relative risk, 0.8; 95 percent confidence interval, 0.6 to 1.0). CONCLUSIONS: Early beclomethasone therapy did not prevent bronchopulmonary dysplasia but was associated with lower rates of use of systemic glucocorticoid therapy and mechanical ventilation. (+info)An isolated perfused rat lung preparation. (8/3997)
An isolated perfused rat lung preparation (IPL) is described and its physiologic status is evaluated. The evaluation includes light and electron microscopy after perfusion and estimations of substrate utilization. ATP content, lactate production, and incorporation of glucose carbons into lipids and CO2. It is concluded that the IPL is useful for short-term metabolic and physiologic experiments and offers some unique advantages in evaluating effects of reactive gases upon lung function. (+info)The term "Cheyne-Stokes" was first used to describe this type of respiration by British physician William Cheyne in 1832, and later popularized by John Stokes in 1854. It is also known as "stop-and-go breathing" or "alternating apnea."
Cheyne-Stokes respiration is thought to be caused by changes in the autonomic nervous system that regulate breathing, which can be influenced by various factors such as heart failure, anemia, and medications. The exact mechanisms underlying this phenomenon are not fully understood, but it is believed to involve a complex interplay between cardiac output, venous return, and respiratory muscle function.
The clinical significance of Cheyne-Stokes respiration lies in its potential impact on patient outcomes. It can lead to hypoxia (lack of oxygen) and acidosis (excessive acidity), which can worsen cardiorespiratory symptoms and increase the risk of complications such as heart failure exacerbation, respiratory failure, and death.
Diagnosis of Cheyne-Stokes respiration typically involves monitoring of arterial blood gases, electrocardiography (ECG), and chest radiography. Treatment strategies may include addressing underlying conditions such as heart failure or COPD, adjusting medications, and providing respiratory support as needed.
In summary, Cheyne-Stokes respiration is an abnormal breathing pattern characterized by repetitive cycles of shallow and deep breaths, with periods of apnea and hyperpnea. It is commonly seen in patients with cardiorespiratory conditions and can have significant clinical implications.
There are different types of anoxia, including:
1. Cerebral anoxia: This occurs when the brain does not receive enough oxygen, leading to cognitive impairment, confusion, and loss of consciousness.
2. Pulmonary anoxia: This occurs when the lungs do not receive enough oxygen, leading to shortness of breath, coughing, and chest pain.
3. Cardiac anoxia: This occurs when the heart does not receive enough oxygen, leading to cardiac arrest and potentially death.
4. Global anoxia: This is a complete lack of oxygen to the entire body, leading to widespread tissue damage and death.
Treatment for anoxia depends on the underlying cause and the severity of the condition. In some cases, hospitalization may be necessary to provide oxygen therapy, pain management, and other supportive care. In severe cases, anoxia can lead to long-term disability or death.
Prevention of anoxia is important, and this includes managing underlying medical conditions such as heart disease, diabetes, and respiratory problems. It also involves avoiding activities that can lead to oxygen deprivation, such as scuba diving or high-altitude climbing, without proper training and equipment.
In summary, anoxia is a serious medical condition that occurs when there is a lack of oxygen in the body or specific tissues or organs. It can cause cell death and tissue damage, leading to serious health complications and even death if left untreated. Early diagnosis and treatment are crucial to prevent long-term disability or death.
There are several types of apnea that can occur during sleep, including:
1. Obstructive sleep apnea (OSA): This is the most common type of apnea and occurs when the airway is physically blocked by the tongue or other soft tissue in the throat, causing breathing to stop for short periods.
2. Central sleep apnea (CSA): This type of apnea occurs when the brain fails to send the proper signals to the muscles that control breathing, resulting in a pause in breathing.
3. Mixed sleep apnea (MSA): This type of apnea is a combination of OSA and CSA, where both central and obstructive factors contribute to the pauses in breathing.
4. Hypopneic apnea: This type of apnea is characterized by a decrease in breathing, but not a complete stop.
5. Hypercapnic apnea: This type of apnea is caused by an excessive buildup of carbon dioxide in the blood, which can lead to pauses in breathing.
The symptoms of apnea can vary depending on the type and severity of the condition, but may include:
* Pauses in breathing during sleep
* Waking up with a dry mouth or sore throat
* Morning headaches
* Difficulty concentrating or feeling tired during the day
* High blood pressure
* Heart disease
Treatment options for apnea depend on the underlying cause, but may include:
* Lifestyle changes, such as losing weight, avoiding alcohol and sedatives before bedtime, and sleeping on your side
* Oral appliances or devices that advance the position of the lower jaw and tongue
* Continuous positive airway pressure (CPAP) therapy, which involves wearing a mask during sleep to deliver a constant flow of air pressure into the airways
* Bi-level positive airway pressure (BiPAP) therapy, which involves two levels of air pressure: one for inhalation and another for exhalation
* Surgery to remove excess tissue in the throat or correct physical abnormalities that are contributing to the apnea.
When the sinus node is not functioning properly, it can lead to an arrhythmia, or irregular heartbeat. This can cause a variety of symptoms, including palpitations, shortness of breath, fatigue, and dizziness. In some cases, sinus arrhythmia can be caused by underlying medical conditions such as coronary artery disease, high blood pressure, or cardiomyopathy.
There are several types of sinus arrhythmia, including:
* Sinus tachycardia: a rapid heart rate due to an overactive sinus node. This can be caused by stress, anxiety, or physical exertion.
* Sinus bradycardia: a slow heart rate due to a decreased activity in the sinus node. This can be caused by certain medications, age, or underlying medical conditions.
* Sinus arrest: a complete cessation of sinus node activity, leading to a stop in the heartbeat. This is a rare condition and can be caused by a variety of factors, including electrolyte imbalances or certain medications.
Treatment for sinus arrhythmia depends on the underlying cause and the severity of symptoms. In some cases, no treatment may be necessary, while in other cases, medication or procedures such as cardioversion or catheter ablation may be required. It is important to seek medical attention if symptoms persist or worsen over time, as untreated sinus arrhythmia can lead to more serious complications such as stroke or heart failure.
Mitochondrial diseases can affect anyone, regardless of age or gender, and they can be caused by mutations in either the mitochondrial DNA (mtDNA) or the nuclear DNA (nDNA). These mutations can be inherited from one's parents or acquired during embryonic development.
Some of the most common symptoms of mitochondrial diseases include:
1. Muscle weakness and wasting
2. Seizures
3. Cognitive impairment
4. Vision loss
5. Hearing loss
6. Heart problems
7. Neurological disorders
8. Gastrointestinal issues
9. Liver and kidney dysfunction
Some examples of mitochondrial diseases include:
1. MELAS syndrome (Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like episodes)
2. Kearns-Sayre syndrome (a rare progressive disorder that affects the nervous system and other organs)
3. Chronic progressive external ophthalmoplegia (CPEO), which is characterized by weakness of the extraocular muscles and vision loss
4. Mitochondrial DNA depletion syndrome, which can cause a wide range of symptoms including seizures, developmental delays, and muscle weakness.
5. Mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS)
6. Leigh syndrome, which is a rare genetic disorder that affects the brain and spinal cord.
7. LHON (Leber's Hereditary Optic Neuropathy), which is a rare form of vision loss that can lead to blindness in one or both eyes.
8. Mitochondrial DNA mutation, which can cause a wide range of symptoms including seizures, developmental delays, and muscle weakness.
9. Mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS)
10. Kearns-Sayre syndrome, which is a rare progressive disorder that affects the nervous system and other organs.
It's important to note that this is not an exhaustive list and there are many more mitochondrial diseases and disorders that can affect individuals. Additionally, while these diseases are rare, they can have a significant impact on the quality of life of those affected and their families.
Central sleep apnea (CSA) is a type of sleep apnea that occurs when the brain fails to send the proper signals to the muscles that control breathing during sleep. This results in pauses in breathing, which can last for seconds or even minutes and can occur multiple times throughout the night.
CSA is different from obstructive sleep apnea (OSA), which occurs when the airway is physically blocked by a physical obstruction such as excess tissue in the throat. Instead, CSA is caused by a problem in the brain's respiratory control center, which can be due to various factors such as heart failure, stroke, or a brain tumor.
Symptoms of central sleep apnea may include:
* Pauses in breathing during sleep
* Waking up with a dry mouth or sore throat
* Morning headaches
* Fatigue and daytime sleepiness
Treatment for CSA usually involves addressing the underlying cause, such as treating heart failure or stroke. In some cases, therapies such as continuous positive airway pressure (CPAP) or adaptive servo-ventilation (ASV) may be recommended to help regulate breathing during sleep.
It's important to note that CSA is a less common type of sleep apnea compared to OSA, and it's often misdiagnosed or overlooked. If you suspect you or your partner may have central sleep apnea, it's essential to consult with a healthcare professional for proper diagnosis and treatment.
The signs and symptoms of CE can vary depending on the location of the tumor, but they may include:
* Lumps or swelling in the neck, underarm, or groin area
* Fever
* Fatigue
* Weight loss
* Night sweats
* Swollen lymph nodes
* Pain in the affected area
CE is caused by a genetic mutation that leads to uncontrolled cell growth and division. The exact cause of the mutation is not fully understood, but it is believed to be linked to exposure to certain viruses or chemicals.
Diagnosis of CE typically involves a combination of physical examination, imaging tests such as CT scans or PET scans, and biopsy to confirm the presence of cancer cells. Treatment options for CE depend on the stage and location of the tumor, but may include:
* Chemotherapy to kill cancer cells
* Radiation therapy to shrink the tumor
* Surgery to remove the tumor
* Immunotherapy to boost the immune system's ability to fight the cancer
Overall, CE is a rare and aggressive form of cancer that requires prompt diagnosis and treatment to improve outcomes.
Hypercapnia is a medical condition where there is an excessive amount of carbon dioxide (CO2) in the bloodstream. This can occur due to various reasons such as:
1. Respiratory failure: When the lungs are unable to remove enough CO2 from the body, leading to an accumulation of CO2 in the bloodstream.
2. Lung disease: Certain lung diseases such as chronic obstructive pulmonary disease (COPD) or pneumonia can cause hypercapnia by reducing the ability of the lungs to exchange gases.
3. Medication use: Certain medications, such as anesthetics and sedatives, can slow down breathing and lead to hypercapnia.
The symptoms of hypercapnia can vary depending on the severity of the condition, but may include:
1. Headaches
2. Dizziness
3. Confusion
4. Shortness of breath
5. Fatigue
6. Sleep disturbances
If left untreated, hypercapnia can lead to more severe complications such as:
1. Respiratory acidosis: When the body produces too much acid, leading to a drop in blood pH.
2. Cardiac arrhythmias: Abnormal heart rhythms can occur due to the increased CO2 levels in the bloodstream.
3. Seizures: In severe cases of hypercapnia, seizures can occur due to the changes in brain chemistry caused by the excessive CO2.
Treatment for hypercapnia typically involves addressing the underlying cause and managing symptoms through respiratory support and other therapies as needed. This may include:
1. Oxygen therapy: Administering oxygen through a mask or nasal tubes to help increase oxygen levels in the bloodstream and reduce CO2 levels.
2. Ventilation assistance: Using a machine to assist with breathing, such as a ventilator, to help remove excess CO2 from the lungs.
3. Carbon dioxide removal: Using a device to remove CO2 from the bloodstream, such as a dialysis machine.
4. Medication management: Adjusting medications that may be contributing to hypercapnia, such as anesthetics or sedatives.
5. Respiratory therapy: Providing breathing exercises and other techniques to help improve lung function and reduce symptoms.
It is important to seek medical attention if you suspect you or someone else may have hypercapnia, as early diagnosis and treatment can help prevent complications and improve outcomes.
Some common examples of respiration disorders include:
1. Asthma: A chronic condition that causes inflammation and narrowing of the airways, leading to wheezing, coughing, and shortness of breath.
2. Chronic obstructive pulmonary disease (COPD): A progressive lung disease that makes it difficult to breathe, caused by exposure to pollutants such as cigarette smoke.
3. Pneumonia: An infection of the lungs that can cause fever, chills, and difficulty breathing.
4. Bronchitis: Inflammation of the airways that can cause coughing and difficulty breathing.
5. Emphysema: A condition where the air sacs in the lungs are damaged, making it difficult to breathe.
6. Sleep apnea: A sleep disorder that causes a person to stop breathing for short periods during sleep, leading to fatigue and other symptoms.
7. Cystic fibrosis: A genetic disorder that affects the respiratory system and digestive system, causing thick mucus buildup and difficulty breathing.
8. Pulmonary fibrosis: A condition where the lungs become scarred and stiff, making it difficult to breathe.
9. Tuberculosis (TB): A bacterial infection that primarily affects the lungs and can cause coughing, fever, and difficulty breathing.
10. Lung cancer: A type of cancer that originates in the lungs and can cause symptoms such as coughing, chest pain, and difficulty breathing.
These are just a few examples of respiration disorders, and there are many other conditions that can affect the respiratory system and cause breathing difficulties. If you are experiencing any symptoms of respiration disorders, it is important to seek medical attention to receive an accurate diagnosis and appropriate treatment.
1. Obstructive Sleep Apnea (OSA): This is the most common type of sleep apnea, caused by a physical blockage in the throat, such as excess tissue or a large tongue.
2. Central Sleep Apnea (CSA): This type of sleep apnea is caused by a problem in the brain's breathing control center.
3. Mixed Sleep Apnea: This type of sleep apnea is a combination of OSA and CSA.
The symptoms of sleep apnea syndromes can include:
* Loud snoring
* Pauses in breathing during sleep
* Waking up with a dry mouth or sore throat
* Morning headaches
* Difficulty concentrating or feeling tired during the day
If left untreated, sleep apnea syndromes can lead to serious health problems, such as:
* High blood pressure
* Heart disease
* Stroke
* Diabetes
* Depression
Treatment options for sleep apnea syndromes include:
* Lifestyle changes, such as losing weight or quitting smoking
* Oral appliances, such as a mouthpiece to help keep the airway open
* Continuous positive airway pressure (CPAP) therapy, which involves wearing a mask over the nose and/or mouth while sleeping to deliver a constant flow of air
* Bi-level positive airway pressure (BiPAP) therapy, which is similar to CPAP but delivers two different levels of air pressure
* Surgery, such as a tonsillectomy or a procedure to remove excess tissue in the throat.
It's important to seek medical attention if you suspect you have sleep apnea syndromes, as treatment can help improve your quality of life and reduce the risk of serious health problems.
There are several potential causes of hyperventilation, including anxiety, panic attacks, and certain medical conditions such as asthma or chronic obstructive pulmonary disease (COPD). Treatment for hyperventilation typically involves slowing down the breathing rate and restoring the body's natural balance of oxygen and carbon dioxide levels.
Some common signs and symptoms of hyperventilation include:
* Rapid breathing
* Deep breathing
* Dizziness or lightheadedness
* Chest pain or tightness
* Shortness of breath
* Confusion or disorientation
* Nausea or vomiting
If you suspect that someone is experiencing hyperventilation, it is important to seek medical attention immediately. Treatment may involve the following:
1. Oxygen therapy: Providing extra oxygen to help restore normal oxygen levels in the body.
2. Breathing exercises: Teaching the individual deep, slow breathing exercises to help regulate their breathing pattern.
3. Relaxation techniques: Encouraging the individual to relax and reduce stress, which can help slow down their breathing rate.
4. Medications: In severe cases, medications such as sedatives or anti-anxiety drugs may be prescribed to help calm the individual and regulate their breathing.
5. Ventilation support: In severe cases of hyperventilation, mechanical ventilation may be necessary to support the individual's breathing.
It is important to seek medical attention if you or someone you know is experiencing symptoms of hyperventilation, as it can lead to more serious complications such as respiratory failure or cardiac arrest if left untreated.
Example sentence: "The patient was diagnosed with lactic acidosis secondary to uncontrolled diabetes and was admitted to the intensive care unit for proper management."
There are two main types of heart failure:
1. Left-sided heart failure: This occurs when the left ventricle, which is the main pumping chamber of the heart, becomes weakened and is unable to pump blood effectively. This can lead to congestion in the lungs and other organs.
2. Right-sided heart failure: This occurs when the right ventricle, which pumps blood to the lungs, becomes weakened and is unable to pump blood effectively. This can lead to congestion in the body's tissues and organs.
Symptoms of heart failure may include:
* Shortness of breath
* Fatigue
* Swelling in the legs, ankles, and feet
* Swelling in the abdomen
* Weight gain
* Coughing up pink, frothy fluid
* Rapid or irregular heartbeat
* Dizziness or lightheadedness
Treatment for heart failure typically involves a combination of medications and lifestyle changes. Medications may include diuretics to remove excess fluid from the body, ACE inhibitors or beta blockers to reduce blood pressure and improve blood flow, and aldosterone antagonists to reduce the amount of fluid in the body. Lifestyle changes may include a healthy diet, regular exercise, and stress reduction techniques. In severe cases, heart failure may require hospitalization or implantation of a device such as an implantable cardioverter-defibrillator (ICD) or a left ventricular assist device (LVAD).
It is important to note that heart failure is a chronic condition, and it requires ongoing management and monitoring to prevent complications and improve quality of life. With proper treatment and lifestyle changes, many people with heart failure are able to manage their symptoms and lead active lives.
There are several possible causes of hypoventilation, including:
1. Respiratory muscle weakness or paralysis: This can be due to a variety of conditions, such as muscular dystrophy, amyotrophic lateral sclerosis (ALS), or spinal cord injury.
2. Chronic respiratory failure: This can be caused by conditions such as chronic obstructive pulmonary disease (COPD), interstitial lung disease, or pulmonary fibrosis.
3. Sleep apnea: Hypoventilation can occur during sleep due to the loss of muscle tone in the diaphragm and other respiratory muscles.
4. Anesthesia-induced hypoventilation: Some anesthetics can suppress the respiratory drive, leading to hypoventilation.
5. Drug overdose or intoxication: Certain drugs, such as opioids and benzodiazepines, can depress the central nervous system and lead to hypoventilation.
6. Trauma: Hypoventilation can occur in patients with severe injuries to the chest or abdomen that impair breathing.
7. Sepsis: Severe infections can cause hypoventilation by suppressing the respiratory drive.
8. Metabolic disorders: Certain metabolic disorders, such as diabetic ketoacidosis, can lead to hypoventilation.
Treatment of hypoventilation depends on the underlying cause and may include oxygen therapy, mechanical ventilation, and addressing any underlying conditions or complications. In some cases, hypoventilation may be a sign of a more severe condition that requires prompt medical attention to prevent further complications and improve outcomes.
The term "decerebrate" comes from the Latin word "cerebrum," which means brain. In this context, the term refers to a state where the brain is significantly damaged or absent, leading to a loss of consciousness and other cognitive functions.
Some common symptoms of the decerebrate state include:
* Loss of consciousness
* Flaccid paralysis (loss of muscle tone)
* Dilated pupils
* Lack of responsiveness to stimuli
* Poor or absent reflexes
* Inability to speak or communicate
The decerebrate state can be caused by a variety of factors, including:
* Severe head injury
* Stroke or cerebral vasculature disorders
* Brain tumors or cysts
* Infections such as meningitis or encephalitis
* Traumatic brain injury
Treatment for the decerebrate state is typically focused on addressing the underlying cause of the condition. This may involve medications to control seizures, antibiotics for infections, or surgery to relieve pressure on the brain. In some cases, the decerebrate state may be a permanent condition, and individuals may require long-term care and support.
Respiratory paralysis can manifest in different ways depending on the underlying cause and severity of the condition. Some common symptoms include:
1. Difficulty breathing: Patients may experience shortness of breath, wheezing, or a feeling of suffocation.
2. Weakened cough reflex: The muscles used for coughing may be weakened or paralyzed, making it difficult to clear secretions from the lungs.
3. Fatigue: Breathing can be tiring and may leave the patient feeling exhausted.
4. Sleep disturbances: Respiratory paralysis can disrupt sleep patterns and cause insomnia or other sleep disorders.
5. Chest pain: Pain in the chest or ribcage can be a symptom of respiratory paralysis, particularly if it is caused by muscle weakness or atrophy.
Diagnosis of respiratory paralysis typically involves a physical examination, medical history, and diagnostic tests such as electroencephalogram (EEG), electromyography (EMG), or nerve conduction studies (NCS). Treatment options vary depending on the underlying cause but may include:
1. Medications: Drugs such as bronchodilators, corticosteroids, and anticholinergics can be used to manage symptoms and improve lung function.
2. Respiratory therapy: Techniques such as chest physical therapy, respiratory exercises, and non-invasive ventilation can help improve lung function and reduce fatigue.
3. Surgery: In some cases, surgery may be necessary to correct anatomical abnormalities or repair damaged nerves.
4. Assistive devices: Patients with severe respiratory paralysis may require the use of assistive devices such as oxygen therapy, ventilators, or wheelchairs to help improve their quality of life.
5. Rehabilitation: Physical therapy, occupational therapy, and speech therapy can all be helpful in improving function and reducing disability.
6. Lifestyle modifications: Patients with respiratory paralysis may need to make lifestyle changes such as avoiding smoke, dust, and other irritants, getting regular exercise, and managing stress to help improve their condition.
Body weight is an important health indicator, as it can affect an individual's risk for certain medical conditions, such as obesity, diabetes, and cardiovascular disease. Maintaining a healthy body weight is essential for overall health and well-being, and there are many ways to do so, including a balanced diet, regular exercise, and other lifestyle changes.
There are several ways to measure body weight, including:
1. Scale: This is the most common method of measuring body weight, and it involves standing on a scale that displays the individual's weight in kg or lb.
2. Body fat calipers: These are used to measure body fat percentage by pinching the skin at specific points on the body.
3. Skinfold measurements: This method involves measuring the thickness of the skin folds at specific points on the body to estimate body fat percentage.
4. Bioelectrical impedance analysis (BIA): This is a non-invasive method that uses electrical impulses to measure body fat percentage.
5. Dual-energy X-ray absorptiometry (DXA): This is a more accurate method of measuring body composition, including bone density and body fat percentage.
It's important to note that body weight can fluctuate throughout the day due to factors such as water retention, so it's best to measure body weight at the same time each day for the most accurate results. Additionally, it's important to use a reliable scale or measuring tool to ensure accurate measurements.
There are several types of respiratory insufficiency, including:
1. Hypoxemic respiratory failure: This occurs when the lungs do not take in enough oxygen, resulting in low levels of oxygen in the bloodstream.
2. Hypercapnic respiratory failure: This occurs when the lungs are unable to remove enough carbon dioxide from the bloodstream, leading to high levels of carbon dioxide in the bloodstream.
3. Mixed respiratory failure: This occurs when both hypoxemic and hypercapnic respiratory failure occur simultaneously.
Treatment for respiratory insufficiency depends on the underlying cause and may include medications, oxygen therapy, mechanical ventilation, and other supportive care measures. In severe cases, lung transplantation may be necessary. It is important to seek medical attention if symptoms of respiratory insufficiency are present, as early intervention can improve outcomes and prevent complications.
1) They share similarities with humans: Many animal species share similar biological and physiological characteristics with humans, making them useful for studying human diseases. For example, mice and rats are often used to study diseases such as diabetes, heart disease, and cancer because they have similar metabolic and cardiovascular systems to humans.
2) They can be genetically manipulated: Animal disease models can be genetically engineered to develop specific diseases or to model human genetic disorders. This allows researchers to study the progression of the disease and test potential treatments in a controlled environment.
3) They can be used to test drugs and therapies: Before new drugs or therapies are tested in humans, they are often first tested in animal models of disease. This allows researchers to assess the safety and efficacy of the treatment before moving on to human clinical trials.
4) They can provide insights into disease mechanisms: Studying disease models in animals can provide valuable insights into the underlying mechanisms of a particular disease. This information can then be used to develop new treatments or improve existing ones.
5) Reduces the need for human testing: Using animal disease models reduces the need for human testing, which can be time-consuming, expensive, and ethically challenging. However, it is important to note that animal models are not perfect substitutes for human subjects, and results obtained from animal studies may not always translate to humans.
6) They can be used to study infectious diseases: Animal disease models can be used to study infectious diseases such as HIV, TB, and malaria. These models allow researchers to understand how the disease is transmitted, how it progresses, and how it responds to treatment.
7) They can be used to study complex diseases: Animal disease models can be used to study complex diseases such as cancer, diabetes, and heart disease. These models allow researchers to understand the underlying mechanisms of the disease and test potential treatments.
8) They are cost-effective: Animal disease models are often less expensive than human clinical trials, making them a cost-effective way to conduct research.
9) They can be used to study drug delivery: Animal disease models can be used to study drug delivery and pharmacokinetics, which is important for developing new drugs and drug delivery systems.
10) They can be used to study aging: Animal disease models can be used to study the aging process and age-related diseases such as Alzheimer's and Parkinson's. This allows researchers to understand how aging contributes to disease and develop potential treatments.
Artificial ventilation
Mouth-to-mouth resuscitation
Robert Spencer (doctor)
Iron lung
Bragg-Paul Pulsator
Charles Leale
Encephalitis
Phyllis Margaret Tookey Kerridge
Soyuz 11
Ventilator
Joseph Demarco
Louis Agassiz Shaw Jr.
Henry Harrington Janeway
History of cardiopulmonary resuscitation
Galen
Holger Nielsen
The Broken Circle Breakdown
History of tracheal intubation
Ricardo Piglia
Tracheal intubation
Fox Spirit Matchmaker
University of Edinburgh
Edward Albert Sharpey-Schafer
USS PC-552
Kim Levin
Waverly B. Woodson Jr.
Indian cobra
George Poe
Emergency medicine reform in Ukraine since 2016
Philip Drinker
Sulfolobus
Blood doping
Chlorophyll fluorescence
Flaccid dysarthria
Lenzman
Brain
Origin of speech
James Braid (surgeon)
First Aid (short story)
Chestnut
Timeline of United States inventions (1890-1945)
Simarouba amara
Wetland
Multiple organ dysfunction syndrome
SS Fenella (1881)
Citrus
Camel
History of medicine
Edgar Lee McWethy Jr.
Apparent death
Blade Runner
Resting state fMRI
Seagrass
Biosphere 2
Bacterial nanowires
Lethal arthrogryposis with anterior horn cell disease
Scaly-foot gastropod
Labor induction
Carl Gunnar Engström
Thirteenth Regional Committee for Europe: Stockholm, 17-20 September 1963: mouth-to-mouth method of artificial respiration: Red...
Respiration, Artificial | Profiles RNS
VDL Groep helps to make Demcon artificial respiration systems
EVKS Elangovan Treated In The ICU With Artificial Respiration
Results of search for 'su:{Respiration, Artificial.}'
›
WHO HQ Library catalog
Unintentional Opiate Overdose Deaths --- King County, Washington,
1990--1999
ICSC 1390 - CYANOGEN
Terminal withdrawal of mechanical ventilation at a long-term acute care hospital: comparison with a medical ICU
DailyMed - BENZTROPINE MESYLATE tablet
Aviation Occupational Health and Safety Regulations
ICSC 1464 - 2,2'-DIMETHYL-4,4'-METHYLENEBIS(CYCLOHEXYLAMINE)
Chlordane | Medical Management Guidelines | Toxic Substance Portal | ATSDR
Love Your Enema | MedPage Today
NIOSHTIC-2 Search Results - Full View
Registration Dossier - ECHA
Skip to Properties
Registration Dossier - ECHA
Core Data, 1989
How to Act after Accidents caused by Electrical Current - Course: Basic skills and knowledge of electrical engineering....
Epiglottitis
Emergency Response Guidebook (ERG): GUIDE 117 (EnvironmentalChemistry.com)
Encephalitis | MedlinePlus
Doxapram
- Doxapram Hydrochloride
Summary Report | CureHunter
Course Catalog | Wiregrass Georgia Technical College
1618 Silweld Pa EC msds 5-08.pdf
HOPOMV Trademark of Wang Xiaohua - Registration Number 6251372 - Serial Number 90050871 :: Justia Trademarks
English Exercises: PASSIVE VOICE Review 03 (Author-Bouabdellah)
Oxygen3
- Artificial respiration or ventilation is used in individuals who have stopped breathing or have RESPIRATORY INSUFFICIENCY to increase their intake of oxygen (O2) and excretion of carbon dioxide (CO2). (ouhsc.edu)
- It has been reported that Erode East MLA EVKS Elangovan is being treated with the help of artificial oxygen. (newsbricks.com)
- In this situation, it has been reported that Ilangovan is being treated in the intensive care unit after being fitted with artificial respiration to balance the oxygen level in the blood. (newsbricks.com)
Ventilation2
- Comparison of artificial neural network (ANN) and partial least squares (PLS) regression models for predicting respiratory ventilation: an exploratory study. (cdc.gov)
- The objective of this study was to assess the potential for using artificial neural networks (ANN) to predict inspired minute ventilation [Formula: see text] during exercise activities. (cdc.gov)
Mechanical1
- Any method of artificial breathing that employs mechanical or non-mechanical means to force the air into and out of the lungs. (ouhsc.edu)
Intensive1
- Within three weeks, Demcon, with the help of VDL, managed to develop, manufacture and test a complete artificial respiration system in the Netherlands that can be used for artificial respiration for corona patients in intensive care units. (vdlmastsolutions.nl)
Victim1
- Give artificial respiration if victim is not breathing. (environmentalchemistry.com)
Medical2
- Respiration, Artificial" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (ouhsc.edu)
- give artificial respiration with the aid of a pocket mask equipped with a one-way valve or other proper respiratory medical device. (environmentalchemistry.com)
People2
- This graph shows the total number of publications written about "Respiration, Artificial" by people in this website by year, and whether "Respiration, Artificial" was a major or minor topic of these publications. (ouhsc.edu)
- Below are the most recent publications written about "Respiration, Artificial" by people in Profiles. (ouhsc.edu)
Patients1
- Patients with breathing difficulties may need artificial respiration. (medlineplus.gov)
Equipment3
- Photo caption: VDL Industrial Modules employee shows the casing of the artificial respiration equipment for Demcon. (vdlmastsolutions.nl)
- The Ministry of Health, Welfare and Sport will distribute the artificial respiration equipment across the hospitals. (vdlmastsolutions.nl)
- Because of a sharp rise in demand for artificial respiration equipment as a result of the coronavirus, Demcon ramped up production considerably. (vdlmastsolutions.nl)
Means1
- It can serve as a means of artificial respiration. (medpagetoday.com)
Treatment1
- Respiration and respiratory treatment: a historical overview. (nih.gov)
Case1
- In case of irregular breathing or respiratory arrest provide artificial respiration. (americanelements.com)
Search1
- Results of search for 'su:{Respiration, Artificial. (who.int)
Save1
- The man took the puppy artificial respiration and heart massage to save. (ukrhotnews.com)
Hard1
- Three VDL companies are working hard on making hundreds of artificial respiration systems for our partner Demcon. (vdlmastsolutions.nl)
Respiratory1
- Respiration and respiratory treatment: a historical overview. (nih.gov)
Method of artificial1
- Any method of artificial breathing that employs mechanical or non-mechanical means to force the air into and out of the lungs. (bvsalud.org)